{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:43Z","timestamp":1789958863590,"version":"4.0.1"},"reference-count":73,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","award":["ON175069"],"award-info":[{"award-number":["ON175069"]}]},{"name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","award":["06\/2018"],"award-info":[{"award-number":["06\/2018"]}]},{"name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","award":["JP 17\/19"],"award-info":[{"award-number":["JP 17\/19"]}]},{"name":"Serbian bilateral project with PR China","award":["ON175069"],"award-info":[{"award-number":["ON175069"]}]},{"name":"Serbian bilateral project with PR China","award":["06\/2018"],"award-info":[{"award-number":["06\/2018"]}]},{"name":"Serbian bilateral project with PR China","award":["JP 17\/19"],"award-info":[{"award-number":["JP 17\/19"]}]},{"name":"The Faculty of Medical Sciences, University of Kragujevac","award":["ON175069"],"award-info":[{"award-number":["ON175069"]}]},{"name":"The Faculty of Medical Sciences, University of Kragujevac","award":["06\/2018"],"award-info":[{"award-number":["06\/2018"]}]},{"name":"The Faculty of Medical Sciences, University of Kragujevac","award":["JP 17\/19"],"award-info":[{"award-number":["JP 17\/19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.<\/jats:p>","DOI":"10.3390\/curroncol29050293","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:59:37Z","timestamp":1652875177000},"page":"3647-3657","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-5921","authenticated-orcid":false,"given":"Zeljko","family":"Todorovic","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Todorovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Markovic","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevena","family":"Ladjevac","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Zdravkovic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Predrag","family":"Djurdjevic","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebojsa","family":"Arsenijevic","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Milovanovic","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Arsenijevic","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Milovanovic","sequence":"additional","affiliation":[{"name":"Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"},{"name":"Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3324\/haematol.2010.036152","article-title":"Chronic lymphocytic leukemia and autoimmunity: A systematic review","volume":"96","author":"Hodgson","year":"2011","journal-title":"Haematologica"},{"key":"ref_2","unstructured":"Noone, A.M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2018). SEER Cancer Statistics Review, 1975\u20132015, National Cancer Institute. Based on November 2017 SEER Data Submission, Posted to the SEERWeb Site."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"ESMO Guidelines Committee. Electronic address: Clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41375-020-0885-y","article-title":"Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors","volume":"35","author":"Mimmi","year":"2021","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.4049\/jimmunol.1500751","article-title":"Chimeric antigen receptor-and TCR-modified T cells enter main street and wall street","volume":"195","author":"Barrett","year":"2015","journal-title":"J. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/ph7121049","article-title":"Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors","volume":"7","author":"Fujiwara","year":"2014","journal-title":"Pharmaceuticals"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: Chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Mancikova, V., and Smida, M. (2021). Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115536"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: Presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_12","first-page":"134","article-title":"Beyond CAR-T cells: Natural killer cells immunotherapy","volume":"154","year":"2020","journal-title":"Med. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical responses with T lymphocytes targeting malignancy-associated \u03ba light chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T Cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-Cell lymphoma and indolent b-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1182\/blood-2018-99-115418","article-title":"Prospective clinical trial of anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia shows a high response rate","volume":"132","author":"Gill","year":"2018","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2018-99-110462","article-title":"Rapid MRD-negative responses in patients with relapsed\/refractory CLL Treated with Liso-Cel, a CD19-directed CAR T-cell product: Preliminary results from transcend CLL 004, a phase 1\/2 study including patients with high-risk disease previously treated with ibrutinib","volume":"132","author":"Siddiqi","year":"2018","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: A phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.2174\/138161212801227023","article-title":"Immune dysfunction in chronic lymphocytic leukemia: The role for immunotherapy","volume":"18","author":"Riches","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_37","first-page":"427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2020.12.033","article-title":"Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia","volume":"29","author":"Cox","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"ref_40","first-page":"1","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"8","author":"Tettamanti","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood-2013-01-475939","article-title":"Exhausting T cells in CLL","volume":"121","author":"Zenz","year":"2013","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.02.001","article-title":"Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: Lessons learned","volume":"108","author":"Can","year":"2022","journal-title":"Exp. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2019-123277","article-title":"Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma","volume":"134","author":"Sakemura","year":"2019","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2212derived factor-1","volume":"96","author":"Burger","year":"2000","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: A novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"612244","DOI":"10.3389\/fimmu.2020.612244","article-title":"T cells in chronic lymphocytic leukemia: A two-edged sword","volume":"11","author":"Vlachonikola","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3324\/haematol.2016.151100","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma","year":"2017","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T cells alone or in combination with ibrutinib for relapsed and\/or refractory CLL","volume":"132","author":"Gauthier","year":"2018","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","article-title":"Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma","volume":"103","author":"Shalabi","year":"2018","journal-title":"Haematologica"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2011-10-387969","article-title":"CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results","volume":"119","author":"Till","year":"2012","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(78)91444-7","article-title":"Chronic lymphocytic leuk\u00e6mia: Clonal origin in a committed b-lymphocyte progenitor","volume":"312","author":"Fialkow","year":"1978","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor\u2013associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1182\/blood-2016-01-692046","article-title":"Chimeric antigen receptor T cells targeting Fc \u03bc receptor selectively eliminate CLL cells while sparing healthy B cells","volume":"128","author":"Faitschuk","year":"2016","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1200\/EDBK_320085","article-title":"CAR T-cell therapy in hematologic malignancies: Clinical role, toxicity, and unanswered questions","volume":"41","author":"Gill","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2003-05-1732","article-title":"Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation","volume":"102","author":"Kaminski","year":"2003","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nitsche, A., Zhang, M., Clauss, T., Siegert, W., Brune, K., and Pahl, A. (2007). Cytokine profiles of cord and adult blood leukocytes: Differences in expression are due to differences in expression and activation of transcription factors. BMC Immunol., 8.","DOI":"10.1186\/1471-2172-8-18"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201cOff-the-Shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Poirot","year":"2015","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: Results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1200\/JCO.2021.39.15_suppl.7516","article-title":"Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product in relapsed\/refractory CD19+ NHL","volume":"39","author":"Shah","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease\u2014Biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2015.00195","article-title":"Utilizing chimeric antigen receptors to direct natural killer cell activity","volume":"6","author":"Hermanson","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Herrera, L., Santos, S., Vesga, M.A., Carrascosa, T., Garcia-Ruiz, J.C., P\u00e9rez-Mart\u00ednez, A., Juan, M., and Eguizabal, C. (2021). The race of CAR therapies: CAR-NK cells for fighting B-cell hematological cancers. Cancers, 13.","DOI":"10.3390\/cancers13215418"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/leu.2017.226","article-title":"Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity","volume":"32","author":"Liu","year":"2018","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-019-0613-7","article-title":"Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia","volume":"34","author":"Quintarelli","year":"2020","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18729","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.trsl.2010.07.008","article-title":"Pluripotent stem cell-derived natural killer cells for cancer therapy","volume":"156","author":"Knorr","year":"2010","journal-title":"Transl. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1002\/cpim.108","article-title":"Purification, culture, and CD19-CAR lentiviral transduction of adult and umbilical cord blood NK cells","volume":"131","author":"Herrera","year":"2020","journal-title":"Curr. Protoc. Immunol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/293\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:14:06Z","timestamp":1760138046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/5\/293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":73,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["curroncol29050293"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29050293","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}